Director/PDMR Shareholding

RNS Number : 0354U

Creo Medical Group PLC

24 July 2020

 

 Creo Medical Group plc

("Creo" or the "Company")

Director/ PDMR Shareholding

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that Charles Spicer, Chairman of Creo, today purchased 24,509 ordinary shares of £0.001 each in the capital of the Company ('Ordinary Shares') via his Self-Invested Personal Pension ('SIPP') at a price of 204 pence per Ordinary Share.

Following this purchase, Charles Spicer holds 118,319 Ordinary Shares in the Company, representing approximately 0.1% of the Company's issued share capital.

The information below, set out in accordance with the requirements of the MAR, provides further detail. 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Charles Spicer
2	Reason for the notification
a)	Position/status	Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each
	Identification code	GB00BZ1BLL44
b)	Nature of the transaction	Purchase of Ordinary Shares via SIPP
c)	Price(s) and volume(s)
			Price(s) 204p	Volume(s) 24,509
d)	Aggregated information
	- Aggregated volume	N/A - single transaction
	- Price
e)	Date of the transaction	24 July 2020
f)	Place of the transaction	London Stock Exchange

Enquires:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Cameron MacRitchie (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About Creo Medical  

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.  

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by its unique full spectrum kamaptive technology to market, enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.  An overview of the Creo Medical device technology portfolio can be seen here:

https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf  

For more information about Creo Medical please see our website, www.creomedical.com

 

END

 

 

DSHFIFEADRISFII